The FDA has ordered MacroGenics to halt enrollment in a phase 2 trial of the biotech’s lead candidate lorigerlimab following severe side effects that led to one patient's death.

A patient has died in a mid-stage study of MacroGenics’ bispecific antibody lorigerlimab in gynecologic cancers, prompting ...

Dr. Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, told NewsNation too much groundbreaking cancer ...

Over a five-year span, women who used complementary and alternative medicine had a greater mortality rate than those who ...

Current guidelines on supplemental imaging for screening women with dense breasts are conflicting and must evolve say experts reacting to the new study findings.

The FDA partially pauses cancer drug trial of lorigerlimab after four safety events, including one death, affecting enrollment in MacroGenics' phase ...

Colorectal cancer rates are surging among younger adults, with those 65 and under now comprising 45% of new diagnoses ...

In a study of adults with cancer, those who developed a mental health condition within the first year after their cancer diagnosis had a higher likelihood of dying over the next few years. The ...

Researchers from Yale University School of Medicine have now found that those who undergo CAM have over three times higher risk of death than those who receive standard therapy. Using CAM alongside st ...

Tseung Kwan O Hospital investigating death of 85-year-old patient with transverse colon cancer, who received stoma surgery on February 7 A Hong Kong patient with colon cancer died three weeks after ...

Colorectal cancer is increasing in younger patients and is now the leading cause of cancer death in those under age 50, yet those patients lack support.

Colorectal cancer is now the leading cause of cancer deaths among individuals aged younger than 50 years, and incidence ...